<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947167</url>
  </required_header>
  <id_info>
    <org_study_id>NET0008</org_study_id>
    <secondary_id>SU-03272009-2039</secondary_id>
    <secondary_id>16186</secondary_id>
    <secondary_id>END0008</secondary_id>
    <nct_id>NCT00947167</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors</brief_title>
  <official_title>A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pamela L. Kunz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients
      treated with this strategy consisting of initial therapy with pertuzumab as a single agent
      and then addition of erlotinib for those who have stable disease or progressive disease at
      three months (Simon design).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Extreme toxicity of Pertuzumab and Erlotinib combination
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR) for All Patients Treated With This Strategy (Simon Design)</measure>
    <time_frame>CT scans are done every 4 cycles (every 12 wks)</time_frame>
    <description>RECIST v1.1 used</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities Assessed by CTCAE Grading Criteria and Assigned Attributions Accordingly</measure>
    <time_frame>AEs are assessed every cycle (every 3 wks)</time_frame>
    <description>by CTCAE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Carcinoid Tumors</condition>
  <condition>Adrenal Gland Tumors</condition>
  <condition>Neuroblastoma</condition>
  <condition>Pancreatic Neuroendocrine Tumors</condition>
  <condition>Multiple Endocrine Neoplasia</condition>
  <arm_group>
    <arm_group_label>Pertuzumab and Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pertuzumab</intervention_name>
    <description>840 mg, 420 mg, iv</description>
    <arm_group_label>Pertuzumab and Erlotinib</arm_group_label>
    <other_name>2C4</other_name>
    <other_name>Omnitarg</other_name>
    <other_name>Genentech</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150 mg, PO</description>
    <arm_group_label>Pertuzumab and Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>Erlotinib hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must be treated at Stanford University Medical Center for the entire length of
        study participation.

          1. Patients must have histologically or cytologically confirmed well-differentiated
             neuroendocrine tumor. Patients must be deemed unresectable due to involvement of
             critical vasculature or adjacent organ invasion or have metastatic disease.

          2. Patients with prior surgical resection who develop radiological or clinical evidence
             of metastatic cancer do not require separate histological or cytological confirmation
             of metastatic disease unless an interval of &gt; 5 years has elapsed between the primary
             surgery and the development of metastatic disease. Clinicians should consider biopsy
             of lesions to establish diagnosis of metastatic disease if there is substantial
             clinical ambiguity regarding the nature or source of apparent metastases.

          3. Prior chemotherapy will be permitted.

          4. Prior or concurrent somatostatin analogue use will be permitted.

          5. Patients must have a primary or metastatic lesion measurable in at least one dimension
             by Modified RECIST criteria (v1.1) within 4 weeks prior to entry of study.

          6. Patients must have ECOG performance status of 0-2.

          7. Patients must be &gt;= 18 years of age.

          8. Laboratory values &lt;= 2 weeks prior to randomization:

               -  Absolute Neutrophil Count (ANC) &gt;= 1.5 x 109/L (&gt;= 1500/mm3)

               -  Platelets (PLT) &gt;= 50 x 109/L (&gt;= 100,000/mm3) (or &gt;= 25 x 109/L (&gt;= 100,000/mm3)
                  if thrombocytopenia is secondary to a non-myelosuppressive cause such as splenic
                  sequestration).

               -  Hemoglobin (Hgb) &gt;= 9 g/dL

               -  Serum creatinine &lt;= 1.5 x ULN

               -  Serum bilirubin &lt;= 1.5 x ULN (&lt;= 3.0 x ULN if liver metastases present)

               -  Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) &lt;= 3.0
                  x ULN (&lt;= 5.0 x ULN if liver metastases present). Note: ERCP or percutaneous
                  stenting may be used to normalize the liver function tests.

               -  Albumin &gt;= 1.5

          9. LVEF by TTE or MUGA &gt;= 50%

         10. Life expectancy &gt;= 12 weeks

         11. Ability to give written informed consent according to local guidelines

        Exclusion Criteria:

          1. Disease-Specific Exclusions

               1. Prior full field radiotherapy &lt;= 4 weeks or limited field radiotherapy &lt;= 2 weeks
                  prior to enrollment. Patients must have recovered from all therapy-related
                  toxicities. The site of previous radiotherapy should have evidence of progressive
                  disease if this is the only site of disease.

               2. Prior biologic or immunotherapy &lt;= 2 weeks prior to registration. Patients must
                  have recovered from all therapy-related toxicities

               3. If history of other primary cancer, subject will be eligible only if she or he
                  has:

                    -  Curatively resected non-melanomatous skin cancer

                    -  Curatively treated cervical carcinoma in situ

                    -  Other primary solid tumor curatively treated with no known active disease
                       present and no treatment administered for the last 3 years

               4. Concurrent use of other investigational agents and patients who have received
                  investigational drugs &lt;= 4 weeks prior to enrollment.

          2. General Medical Exclusions

               1. Subjects known to have chronic or active hepatitis B or C infection with impaired
                  hepatic function (ineligible if AST and ALT &gt; 3.0 x ULN).

               2. History of any medical or psychiatric condition or laboratory abnormality that in
                  the opinion of the investigator may increase the risks associated with study
                  participation or study drug administration or may interfere with the conduct of
                  the study or interpretation of study results

               3. Male subject who is not willing to use adequate contraception upon enrollment
                  into this study and for 6 months following the last dose of second-line treatment

               4. Female subject (of childbearing potential, post-menopausal for less than 6
                  months, not surgically sterilized, or not abstinent) who is not willing to use an
                  oral, patch or implanted contraceptive, double-barrier birth control, or an IUD
                  during the course of the study and for 6 months following the last dose of
                  second-line treatment

               5. Female subject who is breast-feeding or who has positive serum pregnancy test 72
                  hours prior to randomization

               6. Pleural effusion or ascites that causes respiratory compromise (&gt;= CTCAE grade 2
                  dyspnea)

               7. Any of the following concurrent severe and/or uncontrolled medical conditions
                  within 24 weeks of enrollment which could compromise participation in the study:

                    -  Unstable angina pectoris

                    -  Symptomatic congestive heart failure

                    -  Myocardial infarction &lt;= 6 months prior to registration and/or randomization

                    -  Serious uncontrolled cardiac arrhythmia

                    -  Uncontrolled diabetes

                    -  Active or uncontrolled infection

                    -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of
                       the lung

                    -  Chronic renal disease

               8. Patients unwilling to or unable to comply with the protocol

               9. Life expectancy of less than 12 weeks

              10. Current, recent (within 4 weeks of the first infusion of this study), or planned
                  participation in an experimental drug study other than a Genentech-sponsored
                  cancer study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Kunz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Pamela L. Kunz</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pertuzumab and Erlotinib</title>
          <description>pertuzumab: 840 mg, 420 mg, iv
erlotinib: 150 mg, PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pertuzumab Alone</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Erlotinib Added to Pertuzumab</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pertuzumab and Erlotinib</title>
          <description>pertuzumab: 840 mg, 420 mg, iv
erlotinib: 150 mg, PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" lower_limit="34" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (RR) for All Patients Treated With This Strategy (Simon Design)</title>
        <description>RECIST v1.1 used</description>
        <time_frame>CT scans are done every 4 cycles (every 12 wks)</time_frame>
        <population>whole cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab and Erlotinib</title>
            <description>pertuzumab: 840 mg, 420 mg, iv
erlotinib: 150 mg, PO</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR) for All Patients Treated With This Strategy (Simon Design)</title>
          <description>RECIST v1.1 used</description>
          <population>whole cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicities Assessed by CTCAE Grading Criteria and Assigned Attributions Accordingly</title>
        <description>by CTCAE</description>
        <time_frame>AEs are assessed every cycle (every 3 wks)</time_frame>
        <population>whole cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab and Erlotinib</title>
            <description>pertuzumab: 840 mg, 420 mg, iv
erlotinib: 150 mg, PO</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicities Assessed by CTCAE Grading Criteria and Assigned Attributions Accordingly</title>
          <description>by CTCAE</description>
          <population>whole cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <desc>We followed patients until death</desc>
      <group_list>
        <group group_id="E1">
          <title>Pertuzumab and Erlotinib</title>
          <description>pertuzumab: 840 mg, 420 mg, iv
erlotinib: 150 mg, PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>ALT elevation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>AST elevation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Calcium low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Potassium low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to toxicity, thus small number of patients analyzed and limited statistical power.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pamela L. Kunz, MD, Leader GI Oncology Research Group</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-725-8738</phone>
      <email>pkunz@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

